ASCO 2024 | Initial results from Phase I/II Study of luxdegalutamide in mCRPC

Daniel Petrylak • 31 May 2024

ASCO 2024

Daniel Petrylak, MD, Yale School of Medicine, New Haven, CT, comments on initial findings from the Phase I/II study (NCT05067140) of luxdegalutamide, an oral PROTAC AR degrader targeting wild-type and mutant AR ligand-binding domains, in patients with metastatic castration-resistant prostate cancer (mCRPC) who progressed on prior novel hormonal agents (NHAs). No dose-limiting toxicities were observed, supporting ARV-766’s potential in advanced prostate cancer treatment. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consulting or Advisory Role – Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Gilead Sciences; Incyte; Ipsen; Janssen; Lilly; Mirati Therapeutics; Monopteros Therapeutics; Pfizer; Pharmacyclics; Regeneron; Roche; Seagen; Urogen pharma
Research Funding – Advanced Accelerator Applications (Inst); Agensys (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Endocyte (Inst); Genentech (Inst); Gilead Sciences (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Replimune (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Expert Testimony – Celgene; sanofi